| Etretinate administration reduces serum propeptide of type I procollagen level in patients with psoriasis. | |
| | |
MedLine Citation:
|
PMID: 7999596 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The serum carboxyterminal propeptide of type I procollagen (PICP) level in 26 patients with psoriasis was significantly lower than in control subjects (124 +/- 47 and 224 +/- 78 ng/ml, respectively; P < 0.001). The patients were divided into two groups, those treated with etretinate and untreated patients. PICP levels in the treated group were significantly lower than those in the untreated group (P < 0.001), but there was no difference between the control and untreated groups. In addition, there was a negative correlation between PICP levels and the serum etretinate concentration in treated patients (r = -0.622, P < 0.05). There was no difference between procollagen type III aminoterminal propeptide (PIIIP) levels in patients and controls, nor was there any significant difference between etretinate-treated and untreated patients. In cell culture studies, etretinate dose-dependently (from 10(-9) to 10(-5) M) decreased the PICP concentration in the medium of fibroblasts from both healthy subjects and patients. In osteoblast cell culture, PICP levels were reduced only in a high concentration of etretinate (10(-5) M). However, no change was observed in preadipose cells. Our in vivo and in vitro observations indicated that psoriasis per se did not affect either serum PICP or PIIIP levels, but that etretinate had an inhibitory effect on collagen synthesis by fibroblasts. Hence, the administration of etretinate to psoriatic patients is, at least in part, responsible for the reduction of serum PICP levels in these patients. |
| | |
Authors:
|
K Osada; M Seishima; S Mori; M Seishima; M Takemura; A Noma |
Related Documents
:
|
22529626 - Assessment of helicobacter pylori prevalence by scorpion real-time pcr in chronic tonsi... 9390336 - The combination of oral acitretin and bath puva for the treatment of severe psoriasis. 3348966 - Effect of puva on intestinal calcium absorption. 2830656 - Monarthritis of the manubriosternal joint. a follow-up study. 3428306 - A sustained-release formulation of l-dopa (madopar hbs) in the treatment of nocturnal a... 10529706 - Prevalence of anal incontinence in 409 patients investigated for stress urinary inconti... |
Publication Detail:
|
Type: Clinical Trial; Comparative Study; Controlled Clinical Trial; Journal Article |
Journal Detail:
|
Title: The British journal of dermatology Volume: 131 ISSN: 0007-0963 ISO Abbreviation: Br. J. Dermatol. Publication Date: 1994 Nov |
Date Detail:
|
Created Date: 1995-01-25 Completed Date: 1995-01-25 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0004041 Medline TA: Br J Dermatol Country: ENGLAND |
Other Details:
|
Languages: eng Pagination: 655-9 Citation Subset: IM |
Affiliation:
|
Department of Dermatology, Gifu University School of Medicine, Japan. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Cells, Cultured Dose-Response Relationship, Drug Etretinate / blood, pharmacology, therapeutic use* Female Fibroblasts / drug effects, metabolism Humans Male Middle Aged Osteoblasts / drug effects, metabolism Peptide Fragments / biosynthesis, blood* Procollagen / biosynthesis, blood* Psoriasis / blood*, drug therapy, pathology |
| Chemical | |
Reg. No./Substance:
|
0/Peptide Fragments; 0/Procollagen; 0/procollagen Type III-N-terminal peptide; 0/procollagen type I carboxy terminal peptide; 54350-48-0/Etretinate |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Variation in comedonal antibiotic concentrations following application of topical tetracycline for a...
Next Document: Systemic glucocorticoids decrease the synthesis of type I and type III collagen in human skin in viv...